Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 18/20 | 0.71 |
| ▸ | HTR2C | P28335 | 16/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5061706 | 0.89 | HTR2A (0.68) | HTR2AHTR2CKCNH2 | |
| SCHEMBL30343208 | 0.89 | HTR2A (0.68) | HTR2AHTR2CKCNH2 | |
| SCHEMBL15248602 | 0.87 | HTR2A (0.64) | HTR2AHTR2CNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3949182 | 0.87 | HTR2A (0.57) | HTR2AHTR2CKCNH2 | |
| SCHEMBL1165717 | 0.86 | HTR2A (0.68) | HTR2AHTR2CKCNH2 | |
| SCHEMBL5057414 | 0.85 | HTR2A (0.75) | HTR2AHTR2CKCNH2 | |
| SCHEMBL29574176 | 0.85 | HTR2A (0.75) | HTR2AHTR2CKCNH2 | |
| SCHEMBL1166249 | 0.85 | HTR2A (0.70) | HTR2AHTR2CKCNH2 | |
| SCHEMBL4660576 | 0.85 | HTR2A (0.60) | HTR2AHTR2CNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1165407 | 0.85 | HTR2A (0.67) | HTR2AHTR2CKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200138784-A1 | PROCESSES USEFUL FOR THE PREPARATION OF 1-[3-(4-BROMO-2-METHYL-2H-PYRAZOL-3-YL)-4-METHOXY-PHENYL]-3-(2,4-DIFLUORO-PHENYL)-UREA AND CRYSTALLINE FORMS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2020-05-07 | — | — | US | claimed |
| US-10583122-B2 | Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2020-03-10 | — | — | US | claimed |
| US-20190099402-A1 | COMPOSITION OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-04-04 | — | — | US | claimed |
| US-10117851-B2 | Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2018-11-06 | — | — | US | claimed |
| US-20180085351-A1 | COMPOSITION OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2018-03-29 | — | — | US | claimed |
| US-9801856-B2 | Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2017-10-31 | — | — | US | claimed |
| US-20160067216-A1 | COMPOSITION OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2016-03-10 | — | — | US | claimed |
| US-9126946-B2 | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | claimed |
| US-20150210648-A1 | PROCESSES USEFUL FOR THE PREPARATION OF 1-[3-(4-BROMO-2-METHYL-2H-PYRAZOL-3-YL)-4-METHOXY-PHENYL]-3-(2,4-DIFLUORO-PHENYL)-UREA AND CRYSTALLINE FORMS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2015-07-30 | — | — | US | claimed |
| US-9034911-B2 | Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2015-05-19 | — | — | US | claimed |
| EP-2364142-A2 | COMPOSITIONS OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2011-09-14 | — | — | EP | claimed |
| US-20110207790-A1 | PROCESSES USEFUL FOR THE PREPARATION OF 1-[3-(4-BROMO-2-METHYL-2H-PYRAZOL-3-YL)-4-METHOXY-PHENYL]-3-(2,4-DIFLUORO-PHENYL)UREA AND CRYSTALLINE FORMS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2011-08-25 | — | — | US | claimed |
| US-20110207791-A1 | COMPOSITION OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2011-08-25 | — | — | US | claimed |
| WO-2010062321-A1 | PROCESSES USEFUL FOR THE PREPARATION OF 1-[3-(4-BROMO-2-METHYL-2H-PYRAZOL-3-YL)-4-METHOXY-PHENYL]-3-(2,4-DIFLUORO-PHENYL)-UREA AND CRYSTALLINE FORMS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | WO | claimed |
| WO-2010062323-A2 | COMPOSITIONS OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | WO | claimed |
| US-20220160681-A1 | COMPOSITION OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
| US-20200397753-A1 | COMPOSITION OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2020-12-24 | — | — | US | disclosed |
| WO-2010062321-A1 | PROCESSES USEFUL FOR THE PREPARATION OF 1-[3-(4-BROMO-2-METHYL-2H-PYRAZOL-3-YL)-4-METHOXY-PHENYL]-3-(2,4-DIFLUORO-PHENYL)-UREA AND CRYSTALLINE FORMS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010062321-A1 | PROCESSES USEFUL FOR THE PREPARATION OF 1-[3-(4-BROMO-2-METHYL-2H-PYRAZOL-3-YL)-4-METHOXY-PHENYL]-3-(2,4-DIFLUORO-PHENYL)-UREA AND CRYSTALLINE FORMS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010062323-A2 | COMPOSITIONS OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210648-A1 | PROCESSES USEFUL FOR THE PREPARATION OF 1-[3-(4-BROMO-2-METHYL-2H-PYRAZOL-3-YL)-4-METHOXY-PHENYL]-3-(2,4-DIFLUORO-PHENYL)-UREA AND CRYSTALLINE FORMS RELATED THERETO | REN, UACA, IPO4 | HTR2A 4233/4885HTR2C 2559/4885NPC1 1515/4885 |
| US-20180085351-A1 | COMPOSITION OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR2A, HTR5A, HTR1A | HTR2A 1/4885HTR2C 5/4885NPC1 1409/4885 |
| US-20200397753-A1 | COMPOSITION OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR2A, HTR5A, HTR1A | HTR2A 1/4885HTR2C 5/4885NPC1 1409/4885 |
| US-20190099402-A1 | COMPOSITION OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR2A, HTR5A, HTR1A | HTR2A 1/4885HTR2C 5/4885NPC1 1409/4885 |
| US-20160067216-A1 | COMPOSITION OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR2A, HTR5A, HTR1A | HTR2A 1/4885HTR2C 5/4885NPC1 1276/4885 |
| US-20220160681-A1 | COMPOSITION OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR2A, HTR5A, HTR1A | HTR2A 1/4885HTR2C 5/4885NPC1 1409/4885 |
| US-20110207790-A1 | PROCESSES USEFUL FOR THE PREPARATION OF 1-[3-(4-BROMO-2-METHYL-2H-PYRAZOL-3-YL)-4-METHOXY-PHENYL]-3-(2,4-DIFLUORO-PHENYL)UREA AND CRYSTALLINE FORMS RELATED THERETO | IPO4, USO1, UACA | HTR2A 4375/4885HTR2C 2675/4885NPC1 1501/4885 |
| US-10117851-B2 | Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto | HTR2A, HTR5A, HTR1A | HTR2A 1/4885HTR2C 5/4885NPC1 1409/4885 |
| US-10583122-B2 | Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto | HTR2A, HTR5A, HTR1A | HTR2A 1/4885HTR2C 5/4885NPC1 1409/4885 |
| US-20200138784-A1 | PROCESSES USEFUL FOR THE PREPARATION OF 1-[3-(4-BROMO-2-METHYL-2H-PYRAZOL-3-YL)-4-METHOXY-PHENYL]-3-(2,4-DIFLUORO-PHENYL)-UREA AND CRYSTALLINE FORMS RELATED THERETO | REN, UACA, IPO4 | HTR2A 4233/4885HTR2C 2559/4885NPC1 1515/4885 |
| US-20110207791-A1 | COMPOSITION OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR2A, HTR5A, HTR1A | HTR2A 1/4885HTR2C 5/4885NPC1 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.